Tekmira Pharmaceuticals Corporation TKMR shares were little changed in the extended session Thursday after Falcon Edge Capital LP disclosed a 9.9 percent passive stake.
The hedge fund headed by Richard Gerson acquired 2.22 million shares of the drug developer, according to a 13G filing Thursday.
Tekmira launched a Phase I clinical trial of hepatitis B drug TKM-HBV Wednesday, dosing two healthy adults to assess the product's safety.
The company expects to test the prospective treatment later this year on chronically infected patients.
Tekmira is up more than 144 percent in the past six months and changed hands recently at $24.51, up 0.12 percent.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
